Dental Treatment Services Scheme (DTSS) - Service Utilisation and Treatment Need (Lot 9)

Dental Treatment Services Scheme (DTSS) – Service Utilisation and Treatment Need (Lot 9) Since 2002, following agreement between the Department of Health and Children and the GMS Payments Board, data from the DTSS payments database has been transferred routinely to the Oral Health Services Research Centre (OHSRC), in University College, Cork for analysis. Queries have been developed in the OHSRC to provide individual level data on the treatments provided to patients, such as examinations, extractions, fillings, scale and polish, removal/amputation of roots, root treatment (upper and lower anterior teeth), radiographs, partial dentures and full dentures, and also data on the characteristics of the dentist providing services. Click here to download PDF 2.4mb

Standards for the Assessment of Need process under Part 2 of the Disability Act 2005Consultation Process

Standards for the Assessment of Need process under Part 2 of the Disability Act 2005 In 2004, the Irish Government launched the National Disability Strategy as a framework of positive action measures to support the participation of people with disabilities in Irish society. Two new pieces of legislation â?" the Education for Persons with Special Education Needs Act, 2004 (EPSEN Act 2004 hereafter) and the Disability Act, 2005 â?" form an integral part of this strategy and deal with the special education and/or health needs of persons. Click here to download PDF 279kb The Report on the Consultation Process on Standards for the Assessment of Need process as referred to on page 6 of the Standards document above. Click here to download PDF 369kb

Detection of cognitive impairment with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) in adolescents with psychotic symptomatology.

Cognitive impairment has been identified in the early phase of schizophrenia spectrum disorders, and is a major contributor to disease-related disability. While screening tools assessing cognitive impairment have been validated for adult schizophrenic populations, there is a need for brief, easily administered, standardized instruments that provide clinically relevant information for adolescents. This study examines the utility of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) in identifying and quantifying neurocognitive impairment in adolescents with schizophrenia spectrum disorders and other serious psychiatric illnesses. 112 adolescents, including 32 healthy subjects and 80 patients, were administered the RBANS. Patients with psychotic disorders demonstrated significant impairment on the RBANS total score compared to patients with other disorders and healthy controls, but this impairment appeared somewhat less severe than is typically reported for in adult patients with schizophrenia on this measure. The RBANS appears to be sensitive in the detection of neurocognitive impairment in a psychiatric population of adolescents with psychotic symptomatology, and may therefore have utility as a clinical screening instrument and/or neurocognitive outcome measure in this population.

Analysis of need in relation to 'one stop shop' services for young people in Northern Ireland

An analysis of need for 'one stop shop'; drop-in support services in relation to alcohol and drug misuse, undertaken by the PHA for the Health Development Policy Branch of the DHSSPS.

Health matters: what you need to know - E. coli O157

This factsheet for general publiccontains information on E. coli O157, a strain of bacteria that can cause severe disease in humans. Information on prevention is included.

Health matters: What you need to know - malaria

Malaria is a serious, sometimes fatal, disease spread by mosquitoes. It is common in many tropical countries and is caused by a parasite called Plasmodium. This two page leaflet covers the types of parasite that carry malaria, where it is most commonly found and the preventative measures you can take to avoid malaria.

Off to a good start: all you need to know about breastfeeding your baby

This book presents the reasons why mothers and babies benefit from breastfeeding and explains how to breastfeed successfully. It covers issues including how breastfeeding works, positioning and attachment, how to know if breastfeeding is going well, expressing milk, breastfeeding and babies in special care, advice on breastfeeding and bed-sharing, dealing with common problems, fitting breastfeeding into your life, and going back to work.

Health matters: what you need to know - Tuberculosis (TB)

This factsheet describes the symptoms of tuberculosis, how it is caught, who is affected and how it is treated.

What you need to know about Campylobacter

Campylobacter is a bacterium found in the intestines of many types of animals and is the most common bacterial cause of diarrhoeal illness. Campylobacter infections are equally common in males and females, with babies and children in the 0 - 4 age group more likely to be affected. It has been found to be more prevalent during the summer months.

Aganirsen Antisense Oligonucleotide Eye Drops Inhibit Keratitis-Induced Corneal Neovascularization and Reduce Need for Transplantation: The I-CAN Study.

OBJECTIVE: Eye drops of aganirsen, an antisense oligonucleotide preventing insulin receptor substrate-1 expression, inhibited corneal neovascularization in a previous dose-finding phase II study. We aimed to confirm these results in a phase III study and investigated a potential clinical benefit on visual acuity (VA), quality of life (QoL), and need for transplantation. DESIGN: Multicenter, double-masked, randomized, placebo-controlled phase III study. PARTICIPANTS: Analysis of 69 patients with keratitis-related progressive corneal neovascularization randomized to aganirsen (34 patients) or placebo (35 patients). Patients applied aganirsen eye drops (86 μg/day/eye) or placebo twice daily for 90 days and were followed up to day 180. MAIN OUTCOME MEASURES: The primary end point was VA. Secondary end points included area of pathologic corneal neovascularization, need for transplantation, risk of graft rejection, and QoL. RESULTS: Although no significant differences in VA scores between groups were observed, aganirsen significantly reduced the relative corneal neovascularization area after 90 days by 26.20% (P = 0.014). This improvement persisted after 180 days (26.67%, P = 0.012). Aganirsen tended to lower the transplantation need in the intent-to-treat (ITT) population at day 180 (P = 0.087). In patients with viral keratitis and central neovascularization, a significant reduction in transplantation need was achieved (P = 0.048). No significant differences between groups were observed in the risk of graft rejection. However, aganirsen tended to decrease this risk in patients with traumatic/viral keratitis (P = 0.162) at day 90. The QoL analyses revealed a significant improvement with aganirsen in composite and near activity subscores (P = 0.039 and 0.026, respectively) at day 90 in the per protocol population. Ocular and treatment-related treatment-emergent adverse events (TEAEs) were reported in a lower percentage with aganirsen compared with placebo. Only 3 serious TEAEs (2 with aganirsen and 1 with placebo) were considered treatment-related. CONCLUSIONS: This first phase III study on a topical inhibitor of corneal angiogenesis showed that aganirsen eye drops significantly inhibited corneal neovascularization in patients with keratitis. The need for transplantation was significantly reduced in patients with viral keratitis and central neovascularization. Topical application of aganirsen was safe and well tolerated.

What you need to know about E. Coli 0157

E. coli O157 belongs to a large group of bacteria called Escherichia coli (or E. coli for short). Many E. coli are harmless and they occur naturally in the gut of animals and humans. One of these, E. coli O157, which is a harmless germ in cattle can cause a serious disease in humans.

What you need to know about salmonella

Salmonella is a bacterium commonly found in the intestines of humans and animals. It can also be found on raw meats, poultry, eggs and in unpasteurised milk. Salmonella food poisoning (Salmonellosis) is an illness that can occur if live Salmonella bacteria enter the body. The bacteria can attach to the cells lining the intestines where they produce toxins and attack the intestinal cells.